179 related articles for article (PubMed ID: 25043598)
1. Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.
Dugan LL; Tian L; Quick KL; Hardt JI; Karimi M; Brown C; Loftin S; Flores H; Moerlein SM; Polich J; Tabbal SD; Mink JW; Perlmutter JS
Ann Neurol; 2014 Sep; 76(3):393-402. PubMed ID: 25043598
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
3. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
4. In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.
Tian L; Karimi M; Brown CA; Loftin SK; Perlmutter JS
Brain Res; 2014 Jul; 1571():49-60. PubMed ID: 24845719
[TBL] [Abstract][Full Text] [Related]
5. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.
Swanson CR; Joers V; Bondarenko V; Brunner K; Simmons HA; Ziegler TE; Kemnitz JW; Johnson JA; Emborg ME
J Neuroinflammation; 2011 Aug; 8():91. PubMed ID: 21819568
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
7. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Morgan WW; Nelson JF
Brain Res; 2001 Dec; 921(1-2):115-21. PubMed ID: 11720717
[TBL] [Abstract][Full Text] [Related]
8. Validation of nigrostriatal positron emission tomography measures: critical limits.
Karimi M; Tian L; Brown CA; Flores HP; Loftin SK; Videen TO; Moerlein SM; Perlmutter JS
Ann Neurol; 2013 Mar; 73(3):390-6. PubMed ID: 23423933
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of carboxyfullerene on MPP+/MPTP-induced neurotoxicity.
Lin AM; Yang CH; Ueng YF; Luh TY; Liu TY; Lay YP; Ho LT
Neurochem Int; 2004 Jan; 44(2):99-105. PubMed ID: 12971912
[TBL] [Abstract][Full Text] [Related]
10. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
11. Neuroimaging Analysis of the Dopamine Basis for Apathetic Behaviors in an MPTP-Lesioned Primate Model.
Tian L; Xia Y; Flores HP; Campbell MC; Moerlein SM; Perlmutter JS
PLoS One; 2015; 10(7):e0132064. PubMed ID: 26135399
[TBL] [Abstract][Full Text] [Related]
12. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice.
Jourdain S; Morissette M; Morin N; Di Paolo T
J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487
[TBL] [Abstract][Full Text] [Related]
13. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
14. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS
Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459
[TBL] [Abstract][Full Text] [Related]
15. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of riluzole in MPTP-treated mice.
Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y
Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056
[TBL] [Abstract][Full Text] [Related]
17. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
[TBL] [Abstract][Full Text] [Related]
18. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
20. Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Takahata K; Shimazu S; Yoneda F; Ogawa M; Iida Y; Saji H
J Neural Transm (Vienna); 2003 Aug; 110(8):859-69. PubMed ID: 12898342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
